QualityStocks News - La Jolla Pharmaceutical Announces Acquisition of Novel Therapeutic, Significant Management Changes

Share Article

La Jolla acquires GCS-100 for treatment of cancer and chronic organ failure, appoints new CEO and director

Targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, we have the most advanced galectin-3-targeting compound in development

QualityStocks would like to highlight La Jolla Pharmaceutical Co., a publicly traded biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company’s product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure.

In the company’s news Friday, La Jolla Pharmaceutical announced that it has acquired global development and commercialization rights to GCS-100, a novel therapeutic for cancer and chronic organ failure.

GCS-100’s ongoing development as an anti-cancer and anti-fibrotic agent is supported by extensive preclinical and clinical investigation, including phase 1 and phase 2 clinical trials.

La Jolla acquired GCS-100 from privately held Solana Therapeutics Inc. (Solana). In connection with the acquisition, former Solana CEO George F. Tidmarsh, M.D., Ph.D. will serve as La Jolla’s new president and CEO.

“Having been involved in the clinical development of GCS-100 over the past several years, I am thrilled to have the opportunity to continue this compound’s development in the context of La Jolla,” Dr. Tidmarsh stated in the press release. “Targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, we have the most advanced galectin-3-targeting compound in development.”

Dr. Tidmarsh has 22 years of experience in the biotechnology industry, including the successful clinical development of three FDA-approved drugs. In addition to his appointment and also in connection to the acquisition, Saiid Zarrabian was appointed as an independent director of the company. Former members of La Jolla’s management team, including Deirdre Y. Gillespie, M.D., president and CEO, and Gail A. Sloan, CPA, CPA, as well as several former board members, have resigned.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Editor
Visit website